

Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients

Gary Deng, Andrew J. Vickers, K. Simon Yeung, Gabriella M. D'Andrea, Han Xiao, Alexandra S. Heerdt, Steven Sugarman, Tiffany Troso-Sandoval, Andrew D. Seidman, Clifford A. Hudis, and Barrie R. Cassileth

From the Integrative Medicine Service, Department of Epidemiology and Biostatistics, Breast Cancer Medicine Service, and Breast Sloan-Kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, New York, NY.

Submitted April 5, 2007; accepted August 13, 2007.

The study was supported by Grant No. CA098565 from the National Cancer Institute.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Address reprint requests to Gary Deng, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1429 First Ave, New York, NY 10021; e-mail: dengg@mskcc.org.

© 2007 by American Society of Clinical Oncology

0732-183X/07/2535-5584/\$20.00

DOI: 10.1200/JCO.2007.12.0774

A B S T R A C T

Purpose

To determine the immediate and long-term effects of true acupuncture versus sham acupuncture on hot flash frequency in women with breast cancer.

Patients and Methods

Seventy-two women with breast cancer experiencing three or more hot flashes per day were randomly assigned to receive either true or sham acupuncture. Interventions were given twice weekly for 4 consecutive weeks. Hot flash frequency was evaluated at baseline, at 6 weeks, and at 6 months after initiation of treatment. Patients initially randomly assigned to the sham group were crossed over to true acupuncture starting at week 7.

Results

The mean number of hot flashes per day was reduced from 8.7 (standard deviation [SD], 3.9) to 6.2 (SD, 4.2) in the true acupuncture group and from 10.0 (SD, 6.1) to 7.6 (SD, 5.7) in the sham group. True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks, but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; $P = .3$). When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen. This reduction in hot flash frequency persisted for up to 6 months after the completion of treatment.

Conclusion

Hot flash frequency in breast cancer patients was reduced following acupuncture. However, when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance. We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.

J Clin Oncol 25:5584-5590. © 2007 by American Society of Clinical Oncology

INTRODUCTION

A hot flash is a sensation of increased temperature accompanied by peripheral vasodilation and profuse sweating. Feelings of anxiety, palpitations, and sleep disturbance can also occur.¹ Between 50% and 80% of postmenopausal women suffer from hot flashes.²⁻⁵ Hot flashes are associated with treatment for breast cancer due to abrupt menopause or estrogen ablation therapy. Approximately two thirds of breast cancer patients report hot flashes and 60% of these (ie, 40% of all patients) rate their problem as moderately or extremely severe.⁶ An increasing number of breast cancer survivors are taking hormonal therapy, and reduction of hot flashes would make a significant impact on their quality of life.

Estrogen replacement therapy was the treatment of choice for menopausal symptoms for decades. However, use of hormones for this purpose declined when hormones were associated with in-

creased risks of breast cancer, coronary artery disease, stroke, and other thromboembolic events.^{7,8} Moreover, estrogen replacement therapy is contraindicated in estrogen receptor-positive breast cancer patients. Several pharmacologic agents, including megestrol acetate,⁹ clonidine,^{10,11} and selective serotonin reuptake inhibitors (SSRIs), reportedly reduce hot flashes in breast cancer patients.¹²⁻¹⁵ These agents can cause side effects, and they have low patient acceptance. A systematic review concluded that they are not optimal choices for most women.¹⁶

Several natural products have also been investigated for the treatment of hot flashes.¹⁷ Randomized trials have failed to find clinically meaningful effects for soy phytoestrogens,¹⁸⁻²⁵ red clover,²⁶ or black cohosh.²⁷⁻²⁹ Vitamin E, although superior to placebo, produces only a small effect size—an improvement of about one hot flash per day compared with placebo.³⁰

Acupuncture is a complementary medicine modality that originated in traditional Chinese

medicine practices.³¹ Several early-phase, uncontrolled studies suggest that acupuncture may reduce hot flashes in postmenopausal women or in breast cancer patients receiving tamoxifen treatment.^{32,33} However, controlled studies of acupuncture have shown mixed results, as reviewed by Carpenter and Neal.³⁴ Because treatment options for hot flashes are limited, especially for breast cancer patients on hormonal therapy, there has been a strong interest in further evaluation of acupuncture for this indication.^{35,36} We conducted a randomized, controlled trial to determine whether true acupuncture is superior to sham acupuncture for the treatment of hot flashes in breast cancer patients.

PATIENTS AND METHODS

Study Design

This was a randomized, controlled, subject-blinded trial. The duration of the intervention was 4 weeks. The primary end point was hot flash frequency at week 6. At week 7, patients randomly assigned to the sham acupuncture (control) group were crossed over to receive true acupuncture and were evaluated 6 weeks later.

Study Participants

Informed consent was obtained before participant enrollment according to a clinical trial protocol approved by the institutional review board at Memorial Sloan-Kettering Cancer Center. Recruitment took place between November 2002 and December 2005. Inclusion criteria were as follows: undergoing treatment for breast cancer at Memorial Sloan-Kettering Cancer Center; Karnofsky performance score more than 60; and an average of 3 or more hot flashes per day during a 1-week period with a baseline diary. Exclusion criteria were as follows: planned surgery, chemotherapy, radiotherapy, immunotherapy, or initiation or cessation of hormonal therapy during the trial or within 3 weeks before the trial; pharmacologic treatment of hot flashes or any use of SSRIs, unless SSRI dose remained stable for 4 weeks prior to study; skin infection; acupuncture treatment in the 6 weeks prior to study; or acupuncture given specifically for the treatment of hot flashes in the previous 6 months.

Random Assignment

Random assignment of participants was accomplished using a secure, password-protected, institutional computer system that stratified by using

permuted blocks of random length. The system is designed to ensure that allocation cannot be guessed before a patient is registered and cannot be changed afterwards, thus ensuring full allocation concealment. The randomization strata were (1) concurrent treatment (yes/no) with any of the following: selective estrogen receptor modulator, gonadotropin-releasing hormone analog, or aromatase inhibitor; (2) concurrent use of either a hot flash medication or an SSRI; (3) baseline hot flash frequency of more than 7 flashes per day; and (4) menopausal status at diagnosis. After participant registration and random assignment, a research assistant who was otherwise unconnected with the trial accessed allocation and telephoned the acupuncturist with the details of allocation. Patients, researchers, and others involved in patient care were blind to the study group; only the acupuncturists and the designated research assistant were aware of which patients received true and which received placebo treatment.

Intervention

Study participants received twice-weekly treatments for 4 weeks (a total of eight treatment sessions in weeks 1 through 4). The first treatment was given on the day of randomization (day 1). The point prescription was changed during the trial. (See Statistical Methods.) Table 1 shows the final set of 19 acupuncture points used in the true acupuncture group. This prescription was derived from previous reports and from expert opinion, as found in standard acupuncture textbooks. The sham and true acupuncture treatments were delivered by several licensed acupuncturists (not always by the same acupuncturist), according to the staff schedule. All acupuncturists had at least 3 years of formal postgraduate training, had practiced continuously from 3 to 25 years, and were not blinded to treatment-group assignment.

In the true acupuncture group, the needles used were stainless-steel filiform, needles sized 0.20 × 30 mm and manufactured by Seirin Corp (Shizuoka, Japan). After sterile swabbing of the skin, needles were inserted 0.25 to 0.5 inches into the skin at the designated acupuncture points and were manipulated manually to obtain De Qi.³¹ No electrical stimulation or other interventions were applied.

In the sham acupuncture group, Streitberger sham needles sized 0.30 × 30 mm and manufactured by Asiamed (Pullach, Germany)³⁷ were applied a few centimeters away from the points listed in Table 1. Rather than penetrating the skin, the needle retracted inside its handle after insertion through an adhesive tape placed on a plastic supporting ring. This type of sham needle has been shown to have high participant credibility and has been successfully implemented in randomized, controlled trials.³⁸ The frequency and duration of the sham acupuncture intervention were identical to those of true acupuncture. To ensure consistency in technique, the therapists were coached by a

Table 1. Acupuncture Point Prescription

| Prescription | | Location |
|-----------------------|-------------|--|
| Point | Meridian | |
| DU 14 | du mai | On the midline at the base of the neck, in the depression below the spinous process of the 7th cervical vertebra (C7) |
| GB 20 | gallbladder | Below the occiput, in the hollow between the origins of the sternomastoid and trapezius muscles |
| BL 13 | bladder | 1.5 cun* lateral to the lower border of the spinous process of the 3rd thoracic vertebra (T3) |
| PC 7 | pericardium | At the wrist joint, between the tendons of palmaris longus and flexor carpi radialis |
| H 6 | heart | On the radial side of the tendon of flexor carpi ulnaris, 0.5 cun proximal to wrist crease |
| K 7 | kidney | On the medial aspect of the lower leg, in the depression 2 cun superior the depression between the medial malleolus and the Achilles tendon, on the anterior border of Achilles tendon |
| ST 36 | stomach | Below the knee, 3 cun inferior to the lateral and inferior aspect of the patella, one finger breadth lateral to the anterior crest of the tibia |
| SP 6 | spleen | On the medial side of the lower leg, 3 cun superior to the prominence of the medial malleolus, in a depression close to the medial crest of the tibia |
| Ear shen men | — | Slightly above the anthelical bifurcation into crura, at the margin of the lower side of the superior anthelical crus facing the fossa, in the concavity of the triangular fossa |
| Ear sympathetic point | — | On the inferior anthelical crus at the intersection with the protruding helical brim of the ascending helix, usually slightly covered by the helical brim |

*A cun is an acupuncture measurement unit that is equivalent to the width of the participant's thumb at the distal phalanx.

single acupuncturist who also observed treatments periodically for integrity. Participants randomly assigned to the control group were offered eight sessions of true acupuncture starting at week 7. To aid the blinding process, all patients were asked to relax on the treatment table, gentle music was played, and an eye pillow was offered. In both groups, needles were retained for 20 minutes and then were removed. Participants with lymphedema were not administered needles in the affected arm.

Evaluation

The primary outcome measurement was hot flash frequency. Participants were asked to record the number of hot flash episodes each day. At baseline, participants completed a diary for 1 week within 3 weeks of randomization. Details of SSRIs and medications taken for hot flashes were recorded and were categorized as either no treatment at enrollment or during study or as treatment that was started, stopped, reduced, increased, or maintained during study.

Participants then completed a hot flash diary for 1 day at days 7, 14, 21, 28, and 35 after randomization and again for 1 week starting 6 weeks after randomization. Those randomly assigned to true acupuncture completed a second diary for 1 week at 26 weeks. Those randomly assigned to the sham acupuncture control group were offered the true acupuncture treatment at week 7. If they agreed to cross over to the true acupuncture group, they were asked to complete diaries at 12 and 32 weeks, which were the equivalent of 6 and 26 weeks after their first true acupuncture session. Control participants who declined further acupuncture were asked to complete further diaries only at week 26.

Immediately after the needles were applied during the first treatment session, participants were administered a credibility-of-treatment rating scale.³⁹ They were asked to answer four questions about their treatment on a five-point, Likert scale that ranged from strongly disagree to strongly agree. This scale was used to determine whether participants were able to distinguish between true and placebo treatments.

Participants were asked at 6 weeks and at 6 months after treatment initiation for details of any non-study-administered treatment for hot flashes. At 6 weeks, participants were asked in which group they thought they were allocated (true *v* sham) and why they thought so.

Statistical Methods

Sample-size calculations were based on an initial (unpublished) pilot of 14 participants. The mean baseline hot flash frequency was 7.4, the correlation between baseline and follow-up was 0.64, and the standard deviation (SD) was 2.3. As a conservative measure, we used the upper 75th percentile of the distribution for the SD (2.8) and the lower 75th percentile of the correlation (0.54). By assuming a 25% reduction in hot flash frequency in the placebo group, we specified that a minimum clinically significant difference would be equivalent to a 50% reduction in the true acupuncture group, which would be the equivalent of 1.9 fewer hot flashes per day. This required a total sample size of 66 assessable participants for a power of 90% and an alpha of 5%.

Our prespecified, primary analysis was to compare hot flash frequency at 6 weeks between groups by analysis of covariance, using baseline hot flash frequency and randomization strata as covariates. Differences in the credibility scores were assessed by *t* test. Analysis of medication-use data combined started treatment with increased treatment and combined stopped treatment with reduced treatment. Fisher's exact test was used to test for differences between the groups. All analyses were on the intent-to-treat principle and were conducted using Stata 9.2 (STATA Corp, College Station, TX).

When the study was initially started, 27 participants were accrued and were treated with a set of points different than those shown in Figure 1. At this point, there was a change in staffing. The new group of acupuncturists believed that a different set of points (Table 1) would be more appropriate. We prespecified that we would accrue sufficient patients on the new point prescription to meet the original sample size requirements and that our primary analysis would include only patients on the new point prescription. Seventy-two participants were accrued to this new regimen. Data presented here derived solely from those 72 participants.




Fig 1. Participant flow (description and number of participants). Reasons for withdrawals/drop-outs: (*) one had scheduling conflict, one had disease progression; (†) lost to follow-up; (‡) partial/incomplete diary.

RESULTS

The flow of participants through the trial is shown in Figure 1. Compliance with follow-up was good, with 67 of 72 randomly assigned participants providing data for the primary end point. Baseline data are shown in Table 2. Although there is a chance imbalance in the number of patients per group, the groups are otherwise well matched.

Hot flash frequency over time is shown in Table 3 (absolute number) and in Figure 2 (percentage of baseline). Hot flash frequency was reduced in a similar fashion during the first 2 weeks of the treatment phase in both groups by approximately 20%. Afterwards, the reduction in the sham acupuncture group appears to remain the same, whereas hot flash frequency decreased by approximately another 10% in the true acupuncture group. In the principal analysis (hot flash frequency at week 6), acupuncture was associated with 0.8 fewer hot flashes per day than placebo, but the difference was not statistically significant (95% CI, -0.7 to 2.4 ; $P = .3$).

When participants in the sham acupuncture group were crossed over to the true acupuncture group at week 7, hot flash frequency was reduced by approximately another 20% at week 12. Hot flash frequency was reduced from 7.3 (SD, 5.5) to 5.4 (SD, 3.8), a difference of 1.9 hot flashes per day (95% CI, -0.4 to 4.1). Treatment improvements were maintained at 6 months. There are no obvious differences between groups ($P = .3$) in changes in medication use.

Credibility scores are very similar in each group ($P = .99$), which suggests that blinding was maintained. Participant guesses as to treatment allocation at the poststudy debriefing are given in Table 4.

Table 2. Baseline Characteristics of Sample

| Variable | True Acupuncture | Sham Acupuncture |
|----------------------|------------------|------------------|
| No. of participants | 42 | 30 |
| Age | | |
| Median | 55 | 56 |
| Interquartile range | 48-59 | 49-59 |
| Other treatment | | |
| Tamoxifen | | |
| No. of participants | 20 | 10 |
| % | 48 | 33 |
| Aromatase inhibitors | | |
| No. of participants | 8 | 9 |
| % | 19 | 30 |
| SSRIs | | |
| No. of participants | 16 | 9 |
| % | 38 | 30 |
| Postmenopausal | | |
| No. of participants | 38 | 29 |
| % | 90 | 97 |
| Lymphedema* | | |
| No. of participants | 24 | 18 |
| % | 60 | 60 |
| Credibility scores† | | |
| No. of participants | 35 | 29 |
| Mean | 3.8 | 3.8 |
| Standard deviation | 0.4 | 0.5 |

Abbreviation: SSRIs, selective serotonin reuptake inhibitors.
 *Participants with lymphedema received needle application in one arm only.
 †Maximum credibility score, 5; lowest credibility score, 1.

Although differences between groups approach statistical significance ($P = .069$ by Fisher's exact test), almost all participants who made a guess (55 of 59; 93%) explained the reason for their guess in terms of a change in symptoms; regardless of true allocation, participants who experienced a decrease in symptoms guessed that they were in the acupuncture group, and participants who experienced little change guessed that they had been assigned to the control group.

Only very minor adverse effects, such as slight bleeding or bruising at the needle site, were reported, and none required further medical intervention. A total of 14 grade 1 adverse events (of about 560 acupuncture sessions) were recorded by 12 participants as definitely, probably, or likely due to a study intervention. One participant, who was in the sham group, used off-study medication; no subject used acupuncture treatment off-study.

DISCUSSION

In this randomized, controlled trial, both true and sham acupuncture were associated with an initial reduction in hot flash frequency. The reduction by sham acupuncture appeared to reach a plateau after 2 weeks, whereas the reduction by true acupuncture appeared to continue until week 4, when the treatment period ended. Although there was a greater reduction in hot flashes in the true acupuncture group at week 6 (the primary end point), differences between groups were small and did not reach statistical significance. When the participants in the sham group were crossed over to the true acupuncture group, a further reduction of hot flash frequency was observed. The reduction

Table 3. Frequency of Hot Flashes per Day

| Timepoint | Acupuncture | Placebo | Between-Group Comparison | |
|-------------------------|-------------|---------|--------------------------|----------|
| | | | 95% CI | <i>P</i> |
| Baseline | | | | |
| No. of participants | 42 | 29 | | |
| Mean No. of hot flashes | 8.7 | 10.0 | | |
| SD | 3.9 | 6.1 | | |
| During treatment | | | | |
| Day 7 | | | | |
| No. of participants | 39 | 28 | -1.2 to 1.8 | .7 |
| Mean No. of hot flashes | 7.3 | 7.9 | | |
| SD | 4.4 | 5.0 | | |
| Day 14 | | | | |
| No. of participants | 37 | 28 | -1.4 to 1.4 | .99 |
| Mean No. of hot flashes | 6.8 | 7.5 | | |
| SD | 4.4 | 6.1 | | |
| Day 21 | | | | |
| No. of participants | 37 | 29 | -2.3 to 1.5 | .7 |
| Mean No. of hot flashes | 6.9 | 8.1 | | |
| SD | 4.8 | 6.0 | | |
| Day 28 | | | | |
| No. of participants | 38 | 27 | -2.7 to 0.9 | .3 |
| Mean No. of hot flashes | 5.8 | 7.8 | | |
| SD | 4.8 | 5.9 | | |
| Post-treatment | | | | |
| Day 35 | | | | |
| No. of participants | 37 | 25 | -2.5 to 1.0 | .4 |
| Mean No. of hot flashes | 5.9 | 7.5 | | |
| SD | 4.7 | 5.2 | | |
| Week 6* | | | | |
| No. of participants | 39 | 28 | -2.4 to 0.7 | .3 |
| Mean No. of hot flashes | 6.2 | 7.6 | | |
| SD | 4.2 | 5.7 | | |
| Week 12 | | | | |
| No. of participants | — | 17 | | |
| Mean No. of hot flashes | — | 5.8 | | |
| SD | — | 3.9 | | |
| Month 6 | | | | |
| No. of participants | 33 | 17 | | |
| Mean No. of hot flashes | 6.1 | 6.8 | | |
| SD | 4.9 | 5.7 | | |

Abbreviation: SD, standard deviation.
 *Principal end point.

was maintained at a 6-month follow-up. These results did not meet our predefined criteria for clinical significance.

Previous, uncontrolled studies^{32,33} typically have reported reductions in hot flashes following acupuncture. In a study without a non-treatment or a sham control, both acupuncture and applied relaxation reduced hot flashes in breast cancer patients.⁴⁰ When acupuncture and sham acupuncture are evaluated in the same study, the results have been mixed. In a moderately sized, randomized trial comparing true and sham acupuncture for the treatment of menopausal hot flashes ($N = 29$), Huang et al⁴¹ reported a statistically significant difference between true and sham acupuncture for nocturnal hot flashes. In a report of two randomized, controlled studies (one including transdermal placebo and transdermal estrogen treatment, the other including oral estrogen, acupuncture, and applied relaxation), Zaborowska et al⁴² showed that oral estrogens, acupuncture, and




Fig 2. Hot flashes frequency by time on study. Baseline = 100%. Treatment period: week 1 to week 4. (—▲—) true acupuncture group; (—■—) sham acupuncture group.

applied relaxation were all superior to a transdermal, placebo patch treatment. However, the comparison between acupuncture and transdermal placebo was nonrandomized.

In contrast, Vincent et al⁴³ randomly assigned 103 postmenopausal women to true acupuncture or to needle application at nonacupuncture points as a control. Hot flash scores, which incorporated both frequency and severity, were reduced in both groups, but there was no significant difference between the two groups. Similarly, Wyon et al⁴⁴ found that both electroacupuncture and superficial needle application (sham) reduced hot flashes, with no significant difference between the two interventions.

There are several possible explanations of our findings in light of the above previous studies. First, it may be that the interventions used as sham controls were not entirely inactive. For example, it might be that needle application at nonacupuncture points^{43,44} provides a physiologic stimulus that is at least partly active against hot flashes. This possibility is supported by the reports that acupuncture appeared better than a transdermal placebo patch⁴² but not better than superficial needle application.⁴⁴

Second, symptom improvement may result from the natural course of symptoms or from the psychological impact of treatment. In

drug trials with a placebo control, the placebo effect on hot flashes frequency can vary from 13%^{45,46} to 22%.²⁶ Improvement in our sham acupuncture group (24%) is close to that range. All trials of symptoms in which a certain baseline symptom severity is an eligibility criterion will be subject to regression to the mean. It is also widely believed that psychological impact of receiving treatment—the time and attention from a practitioner, and the patient's belief that they will be helped—is of therapeutic value. Both true and sham acupuncture also may create a relaxation effect, which can reduce hot flashes.^{42,47} Kaptchuk et al⁴⁸ have shown in a randomized trial that a sham acupuncture technique, similar to that used in the current study, was superior to an inert pill for the treatment of pain, except during the 2-week placebo run-in.

The third possible explanation for our findings is that the acupuncture intervention may not have been optimal. This may be because the point prescription was inadequate. Most investigators select acupuncture points based on classical theory, previous research reports, and/or expert opinion. This is an inherent limitation of all acupuncture research, because there is no reliable and consistent way to determine what would constitute the ideal prescription.

The fourth possibility is that our method of symptom assessment evaluated hot flash frequency but not severity. However, pooled data from 968 participants in seven clinical trials showed a close correlation between hot flash frequency and hot flash scores.⁴⁹ Given the small effect size, it is unlikely that measuring hot flash severity would have changed the clinical implications of findings in this study.

Another limitation of our study is the reliance on self-reporting of hot flashes. We did not include physiological measurements,^{50,51} such as skin conductance, because techniques available at the time were not easy to implement and because we felt that clinical significance ultimately depended on how patients perceived their symptoms.

Finally, our intervention period may not have been of sufficient duration. This possibility is supported by Figure 2, in which the reduction of hot flash frequency in the true acupuncture group started to deviate from the sham group after week 2 and reached a lower point at week 4, when the intervention period completed. Further reductions might have been seen if true acupuncture had continued beyond week 4. Moreover, additional reductions in hot flash frequency were observed in the sham acupuncture participants after they were crossed-over to true acupuncture.

The mechanism by which acupuncture might improve hot flashes is unclear. It has been hypothesized that acupuncture regulates neurotransmitters involved in thermoregulation.^{52,53} Few data currently support this contention.

In conclusion, hot flash frequency in breast cancer patients was reduced following acupuncture. However, when compared with sham acupuncture, the reduction associated with the acupuncture treatment provided in the current study did not reach statistical significance. We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction in hot flashes.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

Table 4. Subject Guesses As to Allocation Post-Treatment

| Guess | True Acupuncture Allocation | | Sham Acupuncture Allocation | |
|-------------|-----------------------------|----|-----------------------------|----|
| | No. | % | No. | % |
| Acupuncture | 18 | 43 | 5 | 17 |
| Placebo | 18 | 43 | 18 | 60 |
| Unsure | 4 | 10 | 5 | 17 |
| No data | 2 | 5 | 2 | 7 |

AUTHOR CONTRIBUTIONS

Conception and design: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Gabriella M. D'Andrea, Clifford A. Hudis, Barrie R. Cassileth

Administrative support: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Clifford A. Hudis, Barrie R. Cassileth

Provision of study materials or patients: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Gabriella M. D'Andrea, Han Xiao, Alexandra S. Heerdt, Steven Sugarman, Tiffany Troso-Sandoval, Andrew D. Seidman, Clifford A. Hudis, Barrie R. Cassileth

Collection and assembly of data: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Han Xiao, Barrie R. Cassileth

Data analysis and interpretation: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Barrie R. Cassileth

Manuscript writing: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Barrie R. Cassileth

Final approval of manuscript: Gary Deng, Andrew J. Vickers, K. Simon Yeung, Alexandra S. Heerdt, Clifford A. Hudis, Barrie R. Cassileth

REFERENCES

- Kronenberg F: Hot flashes: Phenomenology, quality of life, and search for treatment options. *Exp Gerontol* 29:319-336, 1994
- National Institutes of Health State-of-the-Science Conference statement: Management of menopause-related symptoms. *Ann Intern Med* 142(12 Pt 1):1003-1013, 2005
- Berg G, Gottwall T, Hammar M, et al: Climacteric symptoms among women aged 60-62 in Linköping, Sweden, in 1986. *Maturitas* 10:193-199, 1988
- Stadberg E, Mattsson LA, Milsom I: The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. *Acta Obstet Gynecol Scand* 76(5):442-448, 1997
- Hargrove JT, Eisenberg E: Menopause. *Med Clin North Am* 79:1337-1356, 1995
- Carpenter JS, Andrykowski MA, Cordova M, et al: Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management, and relation to quality of life. *Cancer* 82:1682-1691, 1998
- Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 288:321-333, 2002
- Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. *JAMA* 291:1701-1712, 2004
- Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. *N Engl J Med* 331:347-352, 1994
- Goldberg RM, Loprinzi CL, O'Fallon JR, et al: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. *J Clin Oncol* 12:155-158, 1994
- Pandya KJ, Raubertas RF, Flynn PJ, et al: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. *Ann Intern Med* 132:788-793, 2000
- Loprinzi CL, Pisansky TM, Fonseca R, et al: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. *J Clin Oncol* 16:2377-2381, 1998
- Yanklowitz BA: Giant cell tumor of tendon sheath: A literature review and case report. *J Am Podiatry Assoc* 68:706-711, 1978
- Lee EH, Remmler O, Fernando MA, et al: Robenidine-resistant *Eimeria* spp other than *Eimeria maxima*. *Vet Rec* 99:466-467, 1976
- Bichet DG, Arthus MF, Lonergan M: Is testing with dDAVP useful in detecting carriers of the nephrogenic diabetes insipidus gene? *Nephron* 58:372-373, 1991
- Nelson HD, Vesco KK, Haney E, et al: Non-hormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. *JAMA* 295:2057-2071, 2006
- Kronenberg F, Fugh-Berman A: Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials. *Ann Intern Med* 137:805-813, 2002
- Albertazzi P, Steel SA, Bottazzi M: Effect of pure genistein on bone markers and hot flashes. *Climacteric* 8:371-379, 2005
- Lewis JE, Nickell LA, Thompson LU, et al: A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. *Menopause* 13:631-642, 2006
- Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al: Effect of a combination of isoflavones and *Actaea racemosa* Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: A 12-week randomized, placebo-controlled, double-blind study. *Menopause* 12:412-420, 2005
- MacGregor CA, Canney PA, Patterson G, et al: A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. *Eur J Cancer* 41:708-714, 2005
- Secreto G, Chiechi LM, Amadori A, et al: Soy isoflavones and melatonin for the relief of climacteric symptoms: A multicenter, double-blind, randomized study. *Maturitas* 47:11-20, 2004
- Burke GL, Legault C, Anthony M, et al: Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: The Soy Estrogen Alternative Study. *Menopause* 10:147-153, 2003
- Quella SK, Loprinzi CL, Barton DL, et al: Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. *J Clin Oncol* 18:1068-1074, 2000
- Van Patten CL, Olivetto IA, Chambers GK, et al: Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. *J Clin Oncol* 20:1449-1455, 2002
- Tice JA, Ettinger B, Ensrud K, et al: Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) Study: A randomized controlled trial. *JAMA* 290:207-214, 2003
- Pockaj BA, Gallagher JG, Loprinzi CL, et al: Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. *J Clin Oncol* 24:2836-2841, 2006
- Jacobson JS, Troxel AB, Evans J, et al: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. *J Clin Oncol* 19:2739-2745, 2001
- Newton KM, Reed SD, LaCroix AZ, et al: Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial. *Ann Intern Med* 145:869-879, 2006
- Barton DL, Loprinzi CL, Quella SK, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. *J Clin Oncol* 16:495-500, 1998
- Kaptchuk TJ: Acupuncture: Theory, efficacy, and practice. *Ann Intern Med* 136:374-383, 2002
- Dong H, Ludicke F, Comte I, et al: An exploratory pilot study of acupuncture on the quality of life and reproductive hormone secretion in menopausal women. *J Altern Complement Med* 7:651-658, 2001
- Porzio G, Trapasso T, Martelli S, et al: Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. *Tumori* 88:128-130, 2002
- Carpenter JS, Neal JG: Other complementary and alternative medicine modalities: Acupuncture, magnets, reflexology, and homeopathy. *Am J Med* 118:109-117, 2005 (suppl 12B)
- Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. *Menopause* 11:11-33, 2004
- Philp HA: Hot flashes—a review of the literature on alternative and complementary treatment approaches. *Altern Med Rev* 8:284-302, 2003
- Streitberger K, Kleinhenz J: Introducing a placebo needle into acupuncture research. *Lancet* 352(9125):364-365, 1998
- Kleinhenz J, Streitberger K, Windeler J, et al: Randomised clinical trial comparing the effects of acupuncture and a newly designed placebo needle in rotator cuff tendinitis. *Pain* 83:235-241, 1999
- Guemira F, Souilem J, Issaoui B, et al: [Alpha-thalassemia in the north-east of Tunisia: Three cases of hemoglobinopathy H]. *Tunis Med* 70:489-492, 1992
- Nedstrand E, Wijma K, Wyon Y, et al: Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: A preliminary study. *Climacteric* 8:243-250, 2005
- Huang MI, Nir Y, Chen B, Schnyer R, Manber R: A randomized controlled pilot study of acupuncture for postmenopausal hot flashes: Effect on nocturnal hot flashes and sleep quality. *Fertil Steril* 86:700-710, 2006
- Zaborowska E, Brynhildsen J, Damberg S, et al: Effects of acupuncture, applied relaxation, estrogens and placebo on hot flashes in postmenopausal women: An analysis of two prospective, parallel, randomized studies. *Climacteric* 10:38-45, 2007

43. Vincent A, Barton DL, Mandrekar JN, et al: Acupuncture for hot flashes: A randomized, sham-controlled clinical study. *Menopause* 14:45-52, 2007

44. Wyon Y, Wijma K, Nedstrand E, et al: A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. *Climacteric* 7:153-164, 2004

45. Carpenter JS, Storniolo AM, Johns S, et al: Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. *Oncologist* 12:124-135, 2007

46. Stearns V, Slack R, Greep N, et al: Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial. *J Clin Oncol* 23:6919-6930, 2005

47. Nedstrand E, Wyon Y, Hammar M, et al: Psychological well-being improves in women with breast cancer after treatment with applied relaxation or electro-acupuncture for vasomotor symptom. *J Psychosom Obstet Gynaecol* 27:193-199, 2006

48. Kaptchuk TJ, Stason WB, Davis RB, et al: Sham device v inert pill: Randomised controlled trial of two placebo treatments. *BMJ* 332:391-397, 2006

49. Sloan JA, Loprinzi CL, Novotny PJ, et al: Methodologic lessons learned from hot flash studies. *J Clin Oncol* 19:4280-4290, 2001

50. Carpenter JS, Andrykowski MA, Freedman RR, et al: Feasibility and psychometrics of an ambu-

latory hot flash monitoring device. *Menopause* 6:209-215, 1999

51. de Bakker IP, Everaerd W: Measurement of menopausal hot flushes: Validation and cross-validation. *Maturitas* 25:87-98, 1996

52. Borud EK, Alraek T, White A, et al: The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: A study protocol of an ongoing multi-centre randomised controlled clinical trial. *BMC Complement Altern Med* 7:6, 2007

53. Wyon YA, Spetz AC, Theodorsson GE, et al: Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women. *Menopause* 7:25-30, 2000

Acknowledgment

We thank Bertha Fearon and Tina Chuck (Research Study Assistants); and Yi Chan, Ming Jin, Carole Johnson, Sally Moo Kao, Sissi X. Le, Chunyan Teng, K. Simon Yeung, and Yi Lily Zhang (acupuncturists) for their work in this study. We thank the following investigators for their contribution in recruiting study participants: Patrick Borgen, Jacqueline Bromberg, Mercedes Castiel, Hiram S. Cody, Violante E. Currie, Chau Dang, Maura N. Dickler, Pamela R. Drullinsky, Monica N. Fornier, Daphna Y. Gelblum, Mary L. Gemnignani, Teresa Gilewsky, Arti Hurria, Diane Lake, Nancy E. Mills, Mark M. Moasser, Maryellen Moynahan, Larry Norton, Lisa Scalfani, Nancy T. Sklarin, Maria Theodoulou-Haber, Catherine H. Van Posnak, and Kimberly J. Van Zee.

ERRATUM

The December 10, 2007, article by Deng et al, entitled "Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients" (J Clin Oncol 25:5584-5590, 2007) contained errors.

The following authors were inadvertently omitted from the author list due to a misunderstanding of the authorship criteria:

Gabriella M. D'Andrea, Han Xiao, Steven Sugarman, Tiffany Troso-Sandoval, Andrew D. Seidman, Clifford A. Hudis (Breast Cancer Medicine Service), Alexandra S. Heerdt (Breast Cancer Surgery Service, Memorial-Sloan Kettering Cancer Center, New York, NY)

In the Author Contributions section, each of these authors should have been acknowledged as follows:

Conception and design: Gabriella M. D'Andrea, Clifford A. Hudis

Administrative support: Clifford A. Hudis

Provision of study materials or patients: Gabriella M. D'Andrea, Han Xiao, Steven Sugarman, Tiffany Troso-Sandoval, Andrew D. Seidman, Clifford A. Hudis, Alexandra S. Heerdt

Collection and assembly of data: Han Xiao

Final approval of manuscript: Clifford A. Hudis, Alexandra S. Heerdt

The authors have indicated that no potential conflicts of interest exist. The corrected author list is reprinted below in its entirety.

Gary Deng, Andrew J. Vickers, K. Simon Yeung, Gabriella M. D'Andrea, Han Xiao, Alexandra S. Heerdt, Steven Sugarman, Tiffany Troso-Sandoval, Andrew D. Seidman, Clifford A. Hudis, and Barrie R Cassileth

In the Acknowledgment section, the following investigators should have been acknowledged for their contribution in recruiting study participants:

Patrick Borgen, Jacqueline Bromberg, Mercedes Castiel, Hiram S. Cody, Violante E. Currie, Chau Dang, Maura N. Dickler, Pamela R. Drullinsky, Monica N. Fournier, Daphna Y. Gelblum, Mary L. Gemnignani, Teresa Gilewsky, Arti Hurria, Diane Lake, Nancy E. Mills, Mark M. Moasser, Maryellen Moynahan, Larry Norton, Lisa Sclafani, Nancy T. Sklarin, Maria Theodoulou-Haber, Catherine H. Van Posnak, and Kimberly J. Van Zee

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2008.16.4541
